Spotlights
Dr. Melissa Herbst-Kralovetz’s research team found proteins called immune checkpoint inhibitors in the cervicovaginal environment that may help predict if a woman suffers from abnormal cell growth or cancer.
University of Arizona Health Sciences passes $200 million milestone in research funding in fiscal year 2020, addressing some of the world’s most challenging health conditions, including COVID-19.
Sixteen first-year students are among 32 new PCP Scholarship recipients this academic year at the UArizona Colleges of Medicine in Tucson and Phoenix – both schools still have scholarships available.
Council on Education for Public Health awards full reaccreditation to the Mel and Enid Zuckerman College of Public Health, an exemplary achievement as it celebrates 20th anniversary as part of university.
The Addiction Medicine Fellowship program at the University of Arizona College of Medicine – Tucson will use a $1.4 million federal grant to increase its training capacity, help combat Arizona’s opioid epidemic and increase services to rural and underserved communities across the state.
Dr. Meredith Hay won a $5.7 million grant for clinical trials on a novel peptide therapy that, if successful, would be the first drug to treat vascular dementia – the second most common form of dementia.
Efforts to keep patients safe in the time of COVID-19 led to significant savings and innovation in chemotherapy delivery and earned University of Arizona Health Sciences center national recognition.
Dr. James Galligan and his University of Arizona College of Pharmacy research team found inhibiting glyoxalase-II enzyme results in slower cell growth, which may help limit disease progression.
Dr. Judith Gordon’s research team develops “See Me Serene” project with BIO5 Institute seed funding. Now available free via the App Store and Google Play, it aims to aid people’s mental and physical health.
A study by University of Arizona Health Sciences researchers found that green light therapy resulted in about a 60% reduction in the pain intensity of the headache phase and number of days per month people experienced migraine headaches.